<DOC>
	<DOCNO>NCT00641082</DOCNO>
	<brief_summary>A double-blind randomized , parallel , multicenter 48 week treatment period . The purpose study compare safety antiviral activity 48-week Clevudine Adefovir dipivoxil HBeAg ( - ) Chronic Hepatitis B compensate liver function .</brief_summary>
	<brief_title>A Double-Blind Randomized Clinical Trial Comparing Safety Antiviral Activity 48-week Clevudine Adefovir Dipivoxil HBeAg ( - ) Chronic Hepatitis B With Compensated Liver Function</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<criteria>Patient 18 60 Patient document HBsAg positive &gt; 6 month . Patient compensate hepatic function . Nucleoside treatmentnaÃve subject either gender Patient HBeAg negative . Patient HBV DNA positive DNA level â‰¥ 1 x 10 ( 5 ) copies/mL within 30 day baseline . Patient ALT level range 2 x ULN &lt; 10 X ULN Patient history ascites , variceal hemorrhage hepatic encephalopathy . Exclusion Criteria Patient currently receive antiviral corticosteroid therapy . Patients previously treat lamivudine , adefovir , entecavir , telbivudine , clevudine , lobucavir , famciclovir investigational nucleoside HBV infection . Previous treatment interferon must end least 6 month prior screen visit . Treatment nephrotoxic drug , competitor renal excretion , and/or hepatotoxic drug within 2 month study screen study period Subjects currently participate another investigational study take investigational drug within last 4 week prior screen visit . Patient coinfected HCV , HDV HIV . Patient follow clinical evidence Decompensated liver cirrhosis ( Child class B , C : CPT score 7 ) hepatocellular carcinoma Significant gastrointestinal , renal , bronchopulmonary , neurological , cardiovascular , oncologic allergic disease Previous organ transplantation Patient clinically relevant history abuse alcohol drug . Patient pregnant breastfeeding . Patient unwilling use `` effective '' method contraception study 3 month use study drug cease . Patient Î±Fetoprotein 100ng/mL Patient Hemoglobin &lt; 11g/dL ( Male ) , 10g/dL ( Female ) WBC count &lt; 3,500/mm3 ( PMN &lt; 1,500/mm3 ) Platelet count &lt; 50,000/mm3 Patient creatinine clearance le 60mL/min estimate follow formula : ( 140age year ) ( body weight [ kg ] ) / ( 72 ) ( serum creatinine [ mg/dL ] ) [ Note : multiply estimate 0.85 woman ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>